At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Bavdegalutamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
In Brief
A Phase 1 clinical trial evaluating Bavdegalutamide and Abiraterone for Prostate Cancer Metastatic. Completed, enrolled 45 participants across 18 sites in 4 countries.
Detailed Summary
Phase 1b study to assess the combination of ARV-110 (bavdegalutamide) and abiraterone in participants with metastatic prostate cancer with rising PSA values on abiraterone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer Metastatic
CountriesCanada, France, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartMay 2022
Primary CompletionJul 2024
Study CompletionApr 2025
TodayJul 2026
First PostedJan 4, 2022
Enrollment StartMay 13, 2022
Primary CompletionJul 2, 2024
Study CompletionApr 10, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.5 years ago
Interventions
Bavdegalutamidedrug
Bavdegalutamide oral tablets daily in 28 day cycles.
Abirateronedrug
Abiraterone oral tablets daily at the same dose they were on prior to study enrollment with a concomitant corticosteroid of Investigator's choice as per local label/guidelines.